Prioritizing Itch Relief: New Approaches to Atopic Dermatitis Care

More topical options for atopic dermatitis — but more complexity, too

Atopic dermatitis (AD) is getting a wider array of topical treatments than ever before, but having more options hasn’t automatically made choosing treatments easier for clinicians or patients.

A recent case-based roundtable held in Denver brought together dermatologists from private practice and academic centers to work through a single realistic patient story and tease out how practical issues — not just clinical efficacy — drive decisions in the real world.

Case in focus

The index patient was a 38-year-old man with a long history of atopic dermatitis — 28 years — who now had about 10% body surface area (BSA) involved across his neck, upper chest, and legs.

He reported itch severe enough to disrupt sleep and work, and his disease had been controlled with topicals until a move eight months earlier triggered a prolonged flare that his usual regimen no longer controlled.

Getting severity right: why the label matters

Clinicians vary in how they quantify severity: some rely on the Investigator Global Assessment (IGA), others on Eczema Area and Severity Index (EASI) scores, BSA, or validated itch scales.

Using a formal severity instrument isn’t just academic — it matters for access and timing, because insurance plans often require a severity designation to approve therapies.

Practitioners at the roundtable emphasized that itch and the resulting disruption to sleep and daily function frequently drive urgency more than lesion counts alone, so patient-reported impact should shape treatment choices.

Quality of life as a primary target

Participants reiterated that improving quality of life — sleep, work performance, and family functioning — is a first-order treatment goal rather than an afterthought.

One clinician described how pediatric AD reverberates through a household: exhausted parents, concerned teachers, and siblings affected by sleep disruption, highlighting how disease burden extends beyond skin symptoms.

The limits of the traditional topical ladder

For decades, dermatologists have advanced treatment up a familiar topical ladder: emollients and gentle cleansers, then topical corticosteroids, then topical calcineurin inhibitors (TCIs) like tacrolimus and pimecrolimus, and newer nonsteroidal creams such as crisaborole.

But the group voiced widespread frustration with the real-world limits of some older options, particularly tacrolimus and pimecrolimus, which can sting and lead to nonadherence despite their utility on thin or facial skin (Source: FDA prescribing information for tacrolimus and pimecrolimus).

Clinicians described common mitigation tactics — applying a moisturizer first, diluting TCIs in an emollient, or refrigerating the tube — but agreed that these agents often have modest effect on thicker skin outside the face and flexures.

Crisaborole, a nonsteroidal phosphodiesterase-4 inhibitor cream, was also recognized as a useful addition to the topical toolbox but can cause burning or stinging that limits tolerability, especially in young children (Source: FDA prescribing information for crisaborole).

Patient behavior and product use: a clinical variable

One of the frankest themes during the discussion was how product choices and bathing habits — often shaped by social media — can worsen or perpetuate disease and masquerade as treatment failure.

Clinicians described cases where patients use over-the-counter or influencer-recommended body washes and cleansers that irritate the skin, sometimes with ingredients that sting, or abrasive tools like loofahs that damage the skin barrier.

The practical implication is clear: asking targeted, nonjudgmental questions about skincare routines, bathing frequency, and the exact products patients use is an essential part of every visit because these behaviors affect outcomes.

Where ruxolitinib cream may fit into the sequence

For patients who cannot tolerate topical corticosteroids (TCS) or TCIs, but who are not yet candidates for systemic therapy, ruxolitinib cream (brand name Opzelura, Incyte) has emerged as a meaningful topical option.

The agent was approved by the FDA for mild to moderate atopic dermatitis in non-immunocompromised patients aged 12 years and older (Source: Incyte press release, FDA prescribing information for Opzelura).

In the pivotal phase 3 trials TRuE-AD1 and TRuE-AD2, treatment success on the IGA (defined as score 0 or 1 with at least a 2-grade improvement) was achieved in roughly 50–53% of patients using 1.5% ruxolitinib cream at week 8 versus about 15% with vehicle (Source: Papp et al., TRuE-AD1 and TRuE-AD2; ClinicalTrials.gov NCT03745638, NCT03745651).

The trials also reported EASI-75 responses above 60% and showed meaningful itch reduction in some patients within 12 hours of starting therapy (Source: Papp et al., TRuE-AD1 and TRuE-AD2).

Access and regional variability

Practicing clinicians noted that regional differences in payer policies and state Medicaid formularies affect how early ruxolitinib cream can be used in the treatment sequence.

Some clinicians reported being able to prescribe ruxolitinib before attempting TCIs because local Medicaid coverage allowed it, while other practices need prior authorization or step therapy that requires attempted use of older topicals first (Source: Incyte coverage statements and regional payer policies vary).

Safety considerations: topical versus systemic exposure

Ruxolitinib belongs to the JAK inhibitor class, and the prescribing information carries a boxed warning that highlights risks seen with systemic JAK inhibitors — including serious infections, malignancy, and major cardiovascular events — prompting careful patient selection and counseling (Source: FDA prescribing information for Opzelura).

Roundtable participants stressed the importance of distinguishing topical exposure from systemic exposure in conversations with patients, but also of recognizing that the boxed warning requires clinicians to weigh comorbidities and risk factors when choosing therapy.

Practical clinical priorities from the discussion

Across the case and conversations, the group converged on several practical priorities for topical management of atopic dermatitis.

• Use validated tools — such as EASI, IGA, or a formal itch scale — to define severity and document need for escalation, because these measures support both clinical decisions and payer conversations.

• Treat itch and quality of life impairment as primary targets; relieving itch often improves sleep and function more quickly than focusing only on lesion clearance.

• Make structured patient education a standard part of every visit: ask about bathing habits, product ingredients, and the influence of social media, and offer clear, practical guidance to minimize skin barrier harm.

• Select topical agents not only on efficacy data but also on tolerability, anatomic site, and the patient’s likelihood to adhere to a regimen.

Bottom line

The expanding topical formulary for atopic dermatitis offers important new options like ruxolitinib cream, but real-world decisions depend as much on how clinicians assess severity, educate patients, and navigate payer rules as on clinical trial results.

As the choices grow, the most effective use of topical therapy will come from asking the right questions at each visit and matching the agent to the patient’s symptoms, tolerability, and life context — not just to the label on the prescription.

Sources

1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double‑blind studies. Journal of the American Academy of Dermatology. (TRuE‑AD1 and TRuE‑AD2) (Source: Papp et al., TRuE‑AD1 and TRuE‑AD2).
2. Incyte Corporation. FDA approval and prescribing information for Opzelura (ruxolitinib) topical cream — labeling and press release (Source: Incyte press release; FDA prescribing information for Opzelura).
3. ClinicalTrials.gov. TRuE‑AD1: NCT03745638 and TRuE‑AD2: NCT03745651 (primary phase 3 trial registrations for ruxolitinib cream) (Source: ClinicalTrials.gov).
4. U.S. Food and Drug Administration. Prescribing information and safety labeling for ruxolitinib cream (Opzelura) — boxed warning and safety communications (Source: FDA prescribing information).
5. U.S. Food and Drug Administration. Prescribing information for topical tacrolimus (Protopic) and pimecrolimus (Elidel) — adverse effects and tolerability information (Source: FDA prescribing information for tacrolimus and pimecrolimus).
6. U.S. Food and Drug Administration. Prescribing information for crisaborole (Eucrisa) — tolerability and pediatric use considerations (Source: FDA prescribing information for crisaborole).